BioSpace News Archive

IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, nutrition and ingredients today opens the doors to its Home & Fabric Care Innovation Center at Bell Works in Holmdel, New Jersey.

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced the presentation of a preclinical study conducted by the CarMeN laboratory on the active substance TOTUM-63, at the 55th Annual Meeting of the European Association for the Study of Diabetes being held September 16-20, 2019

A phase 2 clinical trial has found that combining a molecular targeted drug called temsirolimus with chemotherapy shows promise in the treatment of rhabdomyosarcoma, the most common soft tissue sarcoma in childhood

Health Decisions, Inc., a full-service contract research organization specializing in women’s health clinical research and diagnostic development, announced that it has been retained as the Statistical and Clinical Coordinating Center (SCCC) for the Contraceptive Clinical Trials Network (CCTN) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a unit of the National Institutes of Health (NIH).

It was announced that Morledge Family Eye Clinic and Surgery Center in Billings, MT will become part of Vance Thompson Vision’s family of clinics.

Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry

Cancer informatics company selected Sage for recently completed positioning, messaging, and website design

Filterlex Medical, an innovative medical device startup in the cardiovascular field, today announced that the company has been selected for the Phase 2 Horizon 2020 SME Instrument program.

Evan Morris, Ph.D. as VP of Scientific Imaging Research, New Haven.

Varian (NYSE: VAR) has named Francis R. Facchini, M.D., FSIR, as the new chief medical officer, Interventional Oncology, reporting to Dee Khuntia, Varian chief medical officer.